- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
HDL cholesterol inversely associated with cancer risk
Levels of HDL cholesterol and incident cancer risk are significantly inversely associated.
J Am Coll Cardiol. 2010;55:2846-2854. [June 22, 2010]
Levels of high-density lipoprotein cholesterol (HDL-C) and incident cancer risk are significantly inversely associated, and this relationship is independent of factors such as low-density lipoprotein cholesterol (LDL-C), age, and smoking, according to researchers from Tufts Medical Center in Boston. They conducted a meta-analysis of randomized controlled trials of lipid-altering interventions, noting both baseline HDL-C levels and cancer rates. From 24 eligible randomized controlled trials with 8,185 incident cancers and 625,477 person-years of follow-up, the researchers found a significant inverse relationship between baseline HDL-C levels and cancer occurrence. This inverse relationship carried over after adjusting for other variables, such as age, body mass index, diabetes, smoking, sex, and baseline LDL-C. The relative rate of cancer development dropped 36 percent with every 10 mg/dL increase in HDL-C.
